- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05785858
FLUME Catheter Comfort Study
Study Overview
Status
Detailed Description
Background:
Urethral catheters function to drain the urinary bladder when medically indicated or when individuals are unable to empty their bladder by other means. This potential benefit of urinary drainage is balanced by substantial risks of the presence of a urinary catheter in the bladder. While much of the current literature focuses on Catheter Associated Urinary Tract Infections (CAUTI), patients experience substantial pain and discomfort as well. For example, in a cohort of 2000 participants, 50% reported pain or discomfort from the catheter, 20% experienced bladder spasms, and 40% experienced restricted activity1. These non-infectious complications create a substantial burden and decrement in quality of life when a catheter is required.
Rationale:
The Flume catheter is a commercially available catheter (FDA 510(k) cleared) with an innovative catheter design (figure 2). The traditional Foley catheter design includes a protruding tip with drainage holes, which clinically creates edema and disruption of the urothelial lining of the bladder. This protruding tip may also contribute to patient discomfort, pain, and bladder spasms. The Flume catheter is designed such that the balloon envelops the tip on inflation, thus eliminating the protruding catheter tip, while the drainage holes are inset low in the balloon, providing protection to the bladder lining. Based on this change in design, it is plausible that patients may experience less irritation of the urinary bladder, with a concomitant decrease in pain, discomfort, and bladder spasms. The study described herein seeks to compare patient comfort with a traditional catheter vs a Flume catheter.
Flume Catheter Comfort Study is a prospective, observational cohort study comparing patient-reported measures of comfort between the innovative Flume catheter design and the traditional catheter typically used by study participants. Only chronic catheter participants who receive catheter exchanges every 30 days are eligible to participate. As such, a pre-post study design (baseline and 30 day follow up) will allow for individual patients to act as their own control group pre- and post-Flume catheter insertion.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Tullika Garg, MD
- Phone Number: 322301 717-531-0003
- Email: tgarg@pennstatehealth.psu.edu
Study Contact Backup
- Name: Halle Becker
- Phone Number: 717-531-1053
- Email: hbecker3@pennstatehealth.psu.edu
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Department of Urology
-
Principal Investigator:
- Tullika Garg, MD
-
Contact:
- Halle Becker
- Phone Number: 717-531-1053
- Email: hbecker3@pennstatehealth.psu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Document informed consent
- Age ≥ 18 years at time of study entry
- Indwelling urethral catheter use for at least the 3 months prior to study enrollment.
- Able to read, write, and speak English
Exclusion Criteria:
- Indwelling Foley catheter user for shorter than 3 months
- Treatment for a urinary tract infection within 30 days prior to insertion of the Flume catheter, or reporting signs or symptoms of urinary tract infection at the time of catheter change, in the opinion of the treating clinician or site principal investigator.
- Unable to read/write English at a 6th grade level
- Neurologic diagnoses which could decrease/impair bladder sensation (e.g., spinal cord injury, multiple sclerosis)
- History of bladder augmentation or urinary diversion
- Existing catheter related genital adverse effects (e.g., meatal erosion)
- Current use of indwelling catheter larger than 18 Fr in size
- Otherwise unable to participate in or complete study procedures, in the opinion of the principal investigator.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient reported outcomes--Total Neurogenic Bladder Symptom Score Short Form
Time Frame: Baseline and 30 day follow-up
|
Patient reported outcomes will be collected and compared at two time points using the validated Neurogenic Bladder Symptom Score short form.
Scores for the Total Neurogenic Bladder Symptom Score Short Form can range from 0-28, with 0 being the best and 28 being the worst.
|
Baseline and 30 day follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient reported outcomes--Neurogenic Bladder Symptom Score Short Form incontinence domains
Time Frame: Baseline and 30 day follow-up
|
Patient reported outcomes will be collected and compared at two time points using the validated Neurogenic Bladder Symptom Score short form.
Scores for the incontinence domain of the Neurogenic Bladder Symptom Score short form can range from 0 to 12, with 0 being the best and 12 being the worst.
|
Baseline and 30 day follow-up
|
Change in patient reported outcomes--Neurogenic Bladder Symptom Score Short Form quality of life domains
Time Frame: Baseline and 30 day follow-up
|
Patient reported outcomes will be collected and compared at two time points using the validated Neurogenic Bladder Symptom Score short form.
Scores for the quality of life section of the Neurogenic Bladder Symptom Score Short Form domain can range from 0 to 4, with 0 being the best and 4 being the worst.
|
Baseline and 30 day follow-up
|
Change in patient reported outcomes--applicable Genitourinary pain index instrument questions
Time Frame: Baseline and 30 day follow-up
|
Patient reported outcomes will be collected and compared at two time points using the applicable portions of the Genitourinary pain index instrument.
The Genitourinary pain index instrument scores can range from 0 to 31, with 0 being the best and 31 being the worst
|
Baseline and 30 day follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles Scales, MD, Duke Clinical Research Institute
Publications and helpful links
General Publications
- Saint S, Trautner BW, Fowler KE, Colozzi J, Ratz D, Lescinskas E, Hollingsworth JM, Krein SL. A Multicenter Study of Patient-Reported Infectious and Noninfectious Complications Associated With Indwelling Urethral Catheters. JAMA Intern Med. 2018 Aug 1;178(8):1078-1085. doi: 10.1001/jamainternmed.2018.2417.
- Mackay A, Sosland R, Tran K, Stewart J, Boone T, Khavari R. Prospective Evaluation of Intradetrusor Injections of OnabotulinumtoxinA in Adults With Spinal Dysraphism. Urology. 2022 Mar;161:146-152. doi: 10.1016/j.urology.2021.09.045. Epub 2021 Dec 8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00111896
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Retention
-
Rambam Health Care CampusCompleted
-
Mayo ClinicRecruitingPostoperative Urinary RetentionUnited States
-
TriHealth Inc.Completed
-
Lundbeck FoundationCompletedPostoperative Urinary RetentionDenmark
-
Wake Forest University Health SciencesTerminatedUrinary Retention PostoperativeUnited States
-
University of MichiganTerminatedPostoperative Urinary RetentionUnited States
-
University of RochesterTerminatedPost-Operative Urinary RetentionUnited States
-
Rigshospitalet, DenmarkLundbeck FoundationCompletedPostoperative Urinary Retention (POUR)Denmark
-
Anand Rughani, MDMaineHealthCompletedPost-operative Urinary RetentionUnited States
-
University Hospital Inselspital, BerneCompletedPost Operative Urinary RetentionSwitzerland